POST Online Media Lite Edition



 

IBM Watson Health and Pfizer to search for new drugs together

Staff Writer |
IBM Watson Health and Pfizer announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology.

Article continues below






Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool.

Immunotherapies, which modify a patient's immune system to recognize and target cancer cells using a combination of vaccines, immunomodulators, and small/large molecules, are reshaping the field of oncology.

Oncology researchers at Pfizer will use Watson for Drug Discovery to analyze massive volumes of disparate data sources, including licensed and publicly available data as well as Pfizer's proprietary data.

With this new tool, Pfizer researchers will analyze and test hypotheses to generate evidence-based insights for real-time interaction. The customized technology can also support efficient safety assessments.

Cancer is one of the leading causes of death worldwide, and is arguably one of the most complex diseases known to mankind.

Many researchers believe that the future of immuno-oncology lies in combinations tailored to unique tumor characteristics, which could transform the cancer treatment paradigm and enable more oncology patients to be treated.


What to read next

Pfizer offers concessions to win approval for $15bn Hospira takeover
Pfizer considers $100 billion bid for AstraZeneca
Pfizer has green light from EU for $15 billion Hospira acquisition